RECRUITING Phase 2 ClinicalTrials.gov

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

Sponsor: ECOG-ACRIN Cancer Research Group • ClinicalTrials.gov ID: NCT06319027

Registry updated: 2026-08-18

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treatment. Dynamic susceptibility contrast (DSC)-MRIs, along with positron emission tomography (PET) and/or magnetic resonance (MR) spectroscopy, may help doctors tell which changes are a reflection of the treatment and which changes may be due to progressing tumor.

Interventions

Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (Procedure)
Undergo DSC-MRI
Fluciclovine F18 (Other)
Given IV
Gadolinium-Chelate (Drug)
Receive gadolinium-based contrast agent
Magnetic Resonance Spectroscopy (Procedure)
Undergo MR spectroscopy
Positron Emission Tomography (Procedure)
Undergo PET scan

Eligibility criteria

Inclusion Criteria: * Patient must be ≥ 18 years of age. * Patient must have a Karnofsky Performance Status ≥ 60%. * Patient must have newly diagnosed GBM (must be IDH wild type), with pathologic proof, based on World Health Organization (WHO) 2021 criteria. * Patient must be planning to receive standard-of-care treatment for newly diagnosed glioblastoma. * Patient must have completed an MRI prior to the diagnostic surgery for GBM and have images available for upload into Transfer of Images and Data (TRIAD). * Patient must have diagnostic surgery for GBM within 7 weeks prior to registration. * Patient must have O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status ordered at time of registration. * Patient must have a post-operative (op) MRI completed within 3 weeks after diagnostic surgery for GBM and have images available for upload into TRIAD. * Patient must have no contraindications to MRI, including injection of gadolinium-based contrast agents, and demonstrated ability to tolerate MRI on pre-surgical imaging. * Patient must have no allergies to agents that may potentially be used for non-standard of care imaging (18F-fluciclovine, MR contrast). * Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the interventions being used. * All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. * A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). * Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible. * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

Conditions

Glioblastoma, IDH-Wildtype

Locations

University of Alabama at Birmingham Cancer Center — Birmingham, Alabama, United States
Cedars-Sinai Medical Center — Los Angeles, California, United States
Baptist MD Anderson Cancer Center — Jacksonville, Florida, United States
Moffitt Cancer Center — Tampa, Florida, United States
Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia, United States
University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States
Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina, United States
Duke University Medical Center — Durham, North Carolina, United States
Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States
Rhode Island Hospital — Providence, Rhode Island, United States
Edwards Comprehensive Cancer Center — Huntington, West Virginia, United States
West Virginia University Healthcare — Morgantown, West Virginia, United States
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin, United States
University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin, United States
Froedtert Menomonee Falls Hospital — Menomonee Falls, Wisconsin, United States
Medical College of Wisconsin — Milwaukee, Wisconsin, United States
Drexel Town Square Health Center — Oak Creek, Wisconsin, United States
Froedtert West Bend Hospital/Kraemer Cancer Center — West Bend, Wisconsin, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment